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2368 | Nanoscale, 2014, 6, 2368–2374Programmed assembly of polymer–DNA conjugate
nanoparticles with optical readout and sequence-
speciﬁc activation of biorecognition†
Johannes P. Magnusson,a Francisco Ferna´ndez-Trillo,b Giovanna Sicilia,a
Sebastian G. Spain*a and Cameron Alexander*a
Soft micellar nanoparticles can be prepared from DNA conjugates designed to assemble via base pairing
such that strands containing a polymer corona and a cholesterol tail generate controlled supramolecular
architecture. Functionalization of one DNA conjugate strand with a biorecognition ligand results in
shielding of the ligand when in the micelle, while encoding of the DNA sequences with overhangs allows
supramolecular unpacking by addition of a complementary strand and sequence-speciﬁc unshielding of
the ligand. The molecular assembly/disassembly and ‘on–oﬀ’ switch of the recognition signal is
visualized by FRET pair signalling, PAGE and a facile turbidimetric binding assay, allowing direct and
ampliﬁed readout of nucleic acid sequence recognition.Introduction
The encoding of information into materials through monomer
sequence is a central process in nature, utilising components
with A˚ngstrom-scale dimensions to build devices that operate
over nanometre and micron lengthscales. Natural materials of
this type are essentially ‘so’ nanomachines, with structures
that are exible enough to assemble, dissociate and recombine
rapidly, enabling functions such as replication, transcription
and translation. Nucleic acid components of this cellular
machinery have evolved primarily as biological information
storage and transfer materials, but increasingly their potential
as synthetic operators and actuators is being realized as
chemists exploit new DNA and RNA sequences for functions not
previously seen in nature.1–3 These include molecular
computers,4 motors,5 nanoreactors,6 as well as carriers, sensors
and diagnostics.7–12 In addition, the ability to encode ‘dormant’
information in DNA sequences, i.e. structures generated from
paired nucleic acids that are stable until exposed to a comple-
mentary sequence, enables DNA assemblies to be used for logic
operations important in a biomedical context.13,14
A common obstacle in translating a drug candidate from in
vitro eﬃcacy to clinical applicability is ensuring that the active
compound reaches the disease site while minimising oﬀ-target
eﬀects. For most anti-cancer drugs this is particularlyham, University Park, Nottingham, NG7
ottingham.ac.uk; cameron.alexander@
2; Tel: +44 (0)115 846 6272
m, Edgbaston, Birmingham, B15 2TT, UK
(ESI) available: Full experimental
ures. See DOI: 10.1039/c3nr04952cproblematic as they are oen hydrophobic, leading to indis-
criminate diﬀusion into tissue when administered systemically
(intravenously). Combined with the inherent cytotoxicity of
these drugs this leads to severe side eﬀects that limit the
administrable dose and thus clinical eﬃcacy. Encapsulation of
a drug within nanoparticles reduces its ability to permeate into
tissues resulting in increased circulation times. Additionally,
the enhanced permeation and retention (EPR) eﬀect,15,16 where
macromolecules and nanoparticles migrate across the ‘leaky’
vasculature of tumour sites and are retained there, allows for
passive targeting of tumours. A more advanced class of delivery
vehicles are those which that respond to an additional stimulus
so that, once accumulated at the tumour site, they may be
activated to either release the drug or promote cellular uptake.
For example, Salmaso et al. demonstrated that gold nano-
particles coated with a temperature-responsive polymer and
non-temperature responsive polymer bearing folate were only
taken up by folate-receptor positive cells when the responsive
segments were collapsed.17 A similar deshielding approach has
recently been demonstrated by Mirkin et al.18 These examples
used temperature as a stimulus, however temperature is a
‘crude’ stimulus and diﬃcult to control in vivo, thus replace-
ment of the responsive elements with nucleic acid assemblies
should allow for greater specicity. Many elegant studies have
reported the use of DNA-assemblies and logic operators on solid
nanoparticle supports, such as gold, silver, metal oxides and
quantum dots.19–21 While highly eﬀective in diagnostic appli-
cations, ‘hard’ nanoparticles of this type are less attractive from
the viewpoint of combined signalling and therapeutic delivery
applications, as the solid core limits their loading with bioactive
molecules as well as reducing the inherent exibility of the
nanoparticle framework. Furthermore, recent reports haveThis journal is © The Royal Society of Chemistry 2014
Fig. 1 Schematic representation of the structure of DNA conjugates and the unshielding of a ligand via strand displacement. Oligo A holds a PEG
chain to provide shielding, oligo B is complementary to part of oligo A and is modiﬁed with cholesterol and biotin. When annealed the resulting
hybrid forms a micellar structure with the ligand shielded. Oligo C is a DNA sequence complementary to oligo A resulting in strand displacement
and unshielding of the ligand (biotin).
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View Article Onlineindicated that some metal-based nanoparticles can induce pro-
inammatory and pro-apoptotic eﬀects.22–24 Accordingly there
are advantages in the biomedical eld for nanoparticles based
solely on organic components.
Here we aim to demonstrate that ‘so’, and serum-stable
micellar nanoparticles with a nucleic acid reporter function can
be self-assembled from polymer–DNA conjugates. The design
motif utilises a strand-matching architecture to project a shield-
ing polymer corona that hides a biological recognition signal
(biotin). The system was designed to include toehold sequences
in the nucleic acid segments such that the micelles may be
selectively unshielded by addition of a competing complementary
strand resulting in presentation of the signal for binding (Fig. 1).Experimental section
Materials
Oligonucleotides (HPLC puried) except strand A2 were
purchased from biomers.net GmbH (Ulm, Germany) and were
used without purication. Strand A2 (HPLC puried)
was purchased from Sigma-Aldrich and used without further
purication. For sequences and modications see Table 1.
Poly(ethylene glycol) monomethyl ether (Mn 1900 Da) was
purchased from Polysciences Europe GmbH (Eppelheim,
Germany). N,N0-Disuccinimidyl carbonate (95%), tris-borate-
EDTA buﬀer (TBE, 10 concentrate), acrylamide/bis-acrylamide
29/1 (40% solution), ammonium persulfate ($98%), N,N,N0,N0-
tetramethylethylenediamine (TEMED, 99%), orange G, form-
amide (>95.5%, BioReagent), ethylenediaminetetraacetic acid
disodium salt (EDTA, >99%), urea (electrophoresis grade),
tris(hydroxymethyl)aminomethane hydrochloride (tris$HCl,
>99%), acetic acid (>99%), triethylamine (TEA, >99%), glycerol
(>98%), 3-hydroxypicolinic acid (3-HPA), diammonium
hydrogen citrate (DAHC), water (BPC grade), Stains-All (95%),
methylene blue hydrate (>97%), fetal bovine serum (FBS), avidin
(BioUltra, 10–15 units per mg protein) and sodium phospho-
tungstate tribasic hydrate (puriss. p.a.) were purchased
from Sigma-Aldrich (Gillingham, UK). Dulbecco’s phosphate-
buﬀered saline (DPBS, without Ca2+ and Mg2+) was purchased
from Lonza. Anhydrous DMSO (>99.5%, <50 ppm water) wasThis journal is © The Royal Society of Chemistry 2014purchased from Acros. All other solvents were Fisher HPLC or
analytical grade and used without further purication.
Synthesis of a-methoxy-u-succinimidyl carbonate poly-
[ethylene glycol]1900 (mPEG-NHS)
Poly[ethylene glycol] monomethyl ether (Mn 1900 g mol
1, 1.9 g,
1 mmol) was dried by azeotropic distillation with toluene and
then dissolved in dichloromethane/triethylamine/acetonitrile
(4 mL, 2.5/0.5/1). N,N0-Disuccinimidyl carbonate (640 mg,
2.5 mmol) was added and the reaction mixture stirred at room
temperature overnight (16 h). The resulting solution was
precipitated with diethyl ether/petrol and the resulting solid
isolated by centrifugation. The product was puried by disso-
lution in DCM and reprecipitation in diethyl ether/petrol for
two further times.
1H NMR (400 MHz, chloroform-d) d ¼ 4.54–4.39 (m, 2H, CH2
adjacent to carbonate), 3.92–3.44 (m, PEG backbone), 3.39
(s, 3H, MeO–), 2.85 (s, 4H, succinimidyl CH2). NMR analysis was
consistent with >95% conversion of the terminal hydroxyl to the
succinimidyl carbonate.
Synthesis of PEG-A1
Oligo A1 (10 mg, 1.42 mmol) was resuspended in 2 mL of Dul-
becco’s PBS (DPBS) at pH 7.5. mPEG-NHS (14.5 mg, 7.1 mmol)
was dissolved in 200 mL of DMSO and added dropwise to the
oligonucleotide solution. The conjugation was allowed to
proceed for 24 hours. Aer 24 hours the coupling eﬃciency was
examined using high performance liquid chromatography
(HPLC, see below for details). HPLC analysis revealed that only
around 50% of the starting oligonucleotide had coupled to the
PEG in 24 hours, another 2.5 equivalents of mPEG-NHS
(7.25 mg, 3.55 mmol) in 100 mL of DMSO were therefore added to
the reaction and it was allowed to proceed for a further
24 hours. The reaction was again monitored by HPLC aer
48 hours, HPLC analysis showed 66% conversion. Another
5 equivalents of mPEG-NHS (14.5 mg, 7.1 mmol) in 200 mL of
DMSO were added to the reaction and le to react for a further
24 hours. Analysis aer 72 hours revealed that conjugation had
achieved roughly 80% coupling eﬃciency. At this time point
the reaction was stopped and lyophilized. The crude mixture
was resuspended in DNase free water (1 mL) and puried byNanoscale, 2014, 6, 2368–2374 | 2369
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View Article Onlinesemi-preparative HPLC (see conditions below). The volume
collected was concentrated under reduced pressure (to
remove organic solvent) and then subsequently lyophilized
to remove the water. PEG-A1 was collected as a white powder,
the powder was dissolved in DNase free water and quantied
using optical density at 260 nm. In total, 251 OD (7.5 mg,
75% yield) of PEG-A1 were recovered as the pure product.
The product was aliquoted into vials, freeze dried and then
kept at 20 C prior to being used. The pure product was
analysed by MALDI-TOF. Mass expected: 8965 g mol1. Mass
found: 9320 g mol1.
Synthesis of PEG-A3
Oligo A3 (0.5 mg, 0.066 mmol) was resuspended in 188 mL of
Dulbecco PBS (DPBS) at pH 7.5. mPEG-NHS (0.67 mg,
0.328 mmol) was dissolved in 60 mL of DMSO and added
dropwise to the oligonucleotide solution. The conjugation was
allowed to proceed for 24 hours. Aer 24 hours the coupling
eﬃciency was examined using HPLC (see below for details).
HPLC analysis revealed that only around 6% of the starting
oligonucleotide had coupled to the PEG in 24 hours, conse-
quently another 5 equivalents of mPEG-NHS (1.34 mg,
0.656 mmol) in 100 mL of DMSO were added to the reaction and
it was allowed to proceed for a further 24 hours. The reaction
was again monitored by HPLC aer 48 hours, HPLC analysis
showed 44% conversion. Another 2.5 equivalents of mPEG-
NHS (0.67 mg, 0.328 mmol) in 100 mL of DMSO along with
100 mL of THF were added to the reaction and le to react for
another 96 hours. Analysis aer 144 hours revealed that
conjugation had achieved roughly 80% coupling eﬃciency. At
this time the reaction was stopped, the organic solvent was
removed under reduced pressure and the water removed using
lyophilization. The crude mixture was aerwards resuspended
in DNase free water (1 mL) and puried by semi-preparative
HPLC (see conditions below). The solution collected was
concentrated under reduced pressure (to remove organic
solvent) and then subsequently lyophilized to remove the
water. PEG-A3 was collected as a purple powder, which was
dissolved in DNase free water and quantied using optical
density at 260 nm. PEG-A3 (6.3 OD, 180 mg, 36% yield) was
recovered as a pure product. This conjugate was aliquoted into
vials, freeze dried and then kept at 20 C prior to being used.
The identity of the product was determined by MALDI-TOF.
Mass expected: 9520 g mol1. Mass found: 9840 g mol1.
HPLC analysis and purication of DNA strands
Reverse phase high performance liquid chromatography
(RP-HPLC) was performed on a Shimadzu Prominence UPLC
system tted with a DGU-20A5 degasser, LC-20AD low-pressure
gradient pump, CBM-20A LITE system controller, SIL-20A
autosampler and an SPD-M20A diode array detector. Analytical
separations were performed on a Phenomenex Clarity 3 mm
Oligo-RP C18 column (4.6  50 mm) with a gradient of MeOH
(10–70% for PEG-A1 and 35–70% for PEG-A3 over 20 min) in
0.1 M triethylammonium acetate (TEAA, pH 7.5)/MeCN (95/5) at
a ow rate of 1.0 mL min1 as a mobile phase. Semi-preparative2370 | Nanoscale, 2014, 6, 2368–2374separations were performed on a Phenomenex Clarity 3 mm
Oligo-RP C18 column (10  50 mm) under the same conditions
at a ow rate of 5.0 mL min1.
MALDI analysis
Matrix-assisted laser desorption/ionization time-of-ight
(MALDI-TOF) mass spectrometry was performed on a Bruker
MALDI-TOF Ultraex III spectrometer operated in linear,
positive ion mode. 3-HPA containing DAHC was used as the
matrix for the oligonucleotide analysis. Briey, a saturated
solution of 3-HPA (50 mgmL1) was prepared by adding 25 mg
of 3-HPA to 500 mL of 50% ACN/water. 25 mL of DAHC solution
(100 mg mL1) was added to 225 mL of the 3-HPA solution, to
give a nal DAHC concentration of 10 mg mL1. Equal
volumes of matrix solution and ODN solution (0.2 mM) were
mixed and 2 mL of the mixture was spotted onto the MALDI
plate and allowed to dry.
Polyacrylamide gel electrophoresis (PAGE)
Denaturing PAGE
Preparation of samples. Samples were prepared by dilution in
denaturing loading buﬀer and heating to 95 C for 2 minutes
before rapid cooling ice.
Preparation of gels. Gel casting solution was prepared by
mixing the components described in Table S2† and carefully
pipetted into preassembled plate. A 10-well comb was inserted
and the gel allowed to set for 45 min.
Electrophoresis. Gels were pre-run for 20 min at 200 V in 1
TBE. Wells were then washed with the same buﬀer and samples
loaded at approximately 200 pmoles per well. Gels were run at
200 V until the Orange G loading dye had migrated oﬀ the
bottom of the gel (approximately 80 min).
Staining. Gels were washed with water then stained with
0.02% methylene blue in 1 TBE for 20 minutes. Excess
stain was removed by destaining with distilled water until
the bands were clear against the background. Images
were recorded using a standard at bed scanner (HP
Scanjet 2710).
Native PAGE
Preparation of samples. Samples were prepared by dilution in
native loading buﬀer. Loading dye (Orange G) was added only to
the ladder.
Preparation of gels. Gel casting solution was prepared by
mixing the components described in Table S2† and carefully
pipetted into preassembled plate. A 10-well comb was inserted
and the gel allowed to set for 45 min.
Electrophoresis. Gels were pre-run for 20 min at 200 V in 1
TBE. Wells were washed with the same buﬀer and samples
loaded at approximately 200 pmoles per well. Gels were run at
200 V until the Orange G loading dye was approximately 1 cm
from the bottom of the gel (approximately 80 min).
Staining. Gels were washed with water then stained with
Stains-All staining solution for 20 minutes in the dark.
Staining solution was removed and gels destained until
bands were clearly visible against background. Gels were
imaged as before.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineHybridization of DNA strands
Strands to be hybridized were mixed in equimolar quantities at
a concentration of 50–150 mM in hybridization buﬀer and
placed in a 95 C water bath. The water bath was allowed to cool
to room temperature over a period of 2 hours.Dynamic light-scattering (DLS)
Dynamic light-scattering was performed using a Viscotek 802
DLS instrument tted with an internal laser (l 830  5 nm,
Pmax 60 mW). Hybrid PEG-A1:B1 (50 mM in annealing buﬀer)
was ltered through a 0.45 mm membrane (Whatman Spartan,
regenerated cellulose) prior to analysis. Laser power was
adjusted to until detection rate of at least 300 kcps was ach-
ieved. A series of 10  3 seconds experiments was recorded and
hydrodynamic radii distributions calculated with Viscotek/
Malvern OmniSize3 soware.Transmission electron microscopy
Transmission electron microscopy (TEM) was performed on an
FEI Tecnai 12 Biotwin microscope. Samples were prepared by
rst treating a holey carbon-coated 400 mesh copper TEM grid
with graphene oxide solution (0.1 mg mL1) for 30 min. Excess
graphene oxide solution was wicked away with the aid of lter
paper and the grids dried for 30 min. Oligonucleotide solution
(10 mL, 5 mM) was then placed on the grid; aer 2 minutes the
excess liquid was wicked away with the aid of lter paper and
the sample allowed to dry for 5 min. Samples were stained by
addition of 5 mL of a 3% solution of sodium phosphotungstate
for 1 min before wicking away as before. Samples were then
dried overnight prior to imaging.Stability assay
Hybrid PEG-A1:B1 (50 mM) or A2:C in DPBS were mixed with FBS
at a ratio of 9/1 and incubated at 37 C. Aliquots were removed
at 0, 24, 48 and 72 h. and frozen until later analysis. Samples
were analyzed by native PAGE as described previously.Strand displacement assays
By PAGE. The hybrid to be analyzed was combined with
either complementary (strand C) or scrambled (strand D) DNA
at equimolar quantities in hybridization buﬀer at a nal
concentration of 10 mM for both hybrid and displacement
strand. Samples were incubated at room temperature for 1 h
and then analysed by native PAGE as described previously.
By FRET/uorimetry. Fluorescence experiments were per-
formed using a Varian Cary Eclipse spectrophotometer (lex 494
nm, excitation slit width 2.5mm; lem 519 nm, emission slit width
5 mm). Hybrids PEG-A1:B1 and PEG-A3:B3 were combined at a
4/1 mole ratio in hybridization buﬀer at a total concentration of
5 mM (i.e. 1 mM uorophore). 500 mL aliquots were added to a
uorescence cuvette and the uorescencemeasured over a period
of 10 minutes. Aer this time 25 mL of 100 mM (1 mole equiv.) of
oligonucleotide C or D, or an equivalent volume of buﬀer, was
added to the cuvette and the uorescence measured for a furtherThis journal is © The Royal Society of Chemistry 201430 min. Emission intensities were baseline corrected to the
emission intensity at t ¼ 0 min.
Percentage emission was calculated using background uo-
rescence prior to strand addition as zero and the uorescence of
a solution containing 1 mM strand B3 as 100%. Full emission
spectra were recorded prior to addition of DNA and 30 min post
addition.Avidin–biotin binding assay
Avidin was dissolved in DPBS at a concentration of 0.2 mgmL1
protein (2.5 units per mL) and aliquots (100 mL) were transferred
to the wells of a 96-well plate. 25 mL of PEG-A1:B2 (50 mM) was
added to each well followed by 75 mL of oligo C (100 mM, 6 mol
equiv.), oligo D (100 mM, 6 mol equiv.), or buﬀer alone. Addi-
tional control wells were prepared by combining avidin
(100 mL), buﬀer (25 mL) and oligo C (75 mL). Samples were
incubated for 30 min before the absorbance at 550 nm was
measured using a plate reader (Tecan Innite M200).Results and discussion
Design, synthesis and analysis of polymer–DNA conjugates
The use of nanoparticles in diagnosis and therapy requires the
solving of numerous synthetic and biological challenges. Systems
of this type may need to encapsulate a drug or a signal molecule,
traverse complex biological barriers and then report a disease
event or release a drug at a determined time point and/or a
specic cellular or external cue. A ‘so’ nanoparticle structure is
advantageous in this environment because biological
membranes are inherently exible and a number of studies have
shown that micelle- and vesicle-like nanoparticles exhibit better
biodistribution and cell uptake properties than more rigid
analogues.25–27 In addition, a more uid-like structure at a
nanoparticle surface facilitates macromolecular exchange inter-
actions, such as ligand–receptor interactions or nucleic acid
strand switching. A particularly important example of a switching
operation in the drug delivery context is the need to keep a
recognition ligand on a polymer or particle hidden/dormant but
to expose the specic functionality in response to a biological
trigger. Viruses carry out operations of this type to sequentially
expose cell entry ligands and endosomal escape functionality,
and this ‘hide-reveal’ concept has been used in synthetic viral-
mimetic polymers28,29 and thermo-responsive nanoparticles17,30 to
enhance drug delivery and selective cell entry.
Accordingly, we set out a design concept for ‘hide-reveal’
nanoparticles, utilizing DNA-strand recognition to encode for
sequence specic assembly and derivitisation at the respective
30 and 50 ends of each to direct functionality to the interior and
exterior of the particle as shown schematically in Fig. 1. The
oligonucleotide sequences and the modications required (a) to
assemble the structures, (b) to incorporate an orthogonal bio-
logical recognition signal (biotin), (c) to provide a shielding
polymer at the exterior (PEG), and (d) to unveil the ligand via
competitive strand displacement are given in Table 1.
The primary chain of Oligo A is 22 bases long and
50-modied with a poly(ethylene glycol) chain to provideNanoscale, 2014, 6, 2368–2374 | 2371
Table 1 Sequences and modiﬁcations of oligonucleotides used
Name 50 Sequence 30
A1 Amino TAACAGGATTAGCAGAGCGAGG —
PEG-A1 PEG TAACAGGATTAGCAGAGCGAGG —
A2 — TAACAGGATTAGCAGAGCGAGG —
A3 Amino TAACAGGATTAGCAGAGCGAGG BHQ-1a
PEG-A3 PEG TAACAGGATTAGCAGAGCGAGG BHQ-1a
B1 Cholesterol CCTCGCTCTGCT —
B2 Cholesterol CCTCGCTCTGCT Biotin
B3 Cholesterol CCTCGCTCTGCT Fluorescein
C — CCTCGCTCTGCTAATCCTGTTA —
D — AGGAGAGTAGCGAGCTAGTCAA —
a Black Hole Quencher 1 (Biosearch Technologies).
‡ It should be noted that in lanes 8 and 9 in Fig. 3A and S6 there is an extra band
observed with a molecular weight between that of oligo D and hybrid PEG-A1:B1.
As it also appears in the lane where only oligo D was added we conclude that this is
due to self-assembly of oligo D.
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View Article Onlineprotection and shielding. Oligo B is 50-modied with choles-
terol and the 30-terminus of Oligo B is modied with a biotin
moiety. Oligo B is complementary to the 12 bases at the 30
terminus of oligo A allowing hybridization via Watson–Crick
base-pairing to yield a hybrid that shields the biotin moiety
within the micelle. The 10 base toehold allows disruption of
the hybrid upon addition of Oligo C which is complementary
to the full 22 bases of Oligo A. Displacement of Oligo A results
in unshielding of the micelle exposing the biotin moieties and
making them accessible to bind avidin.
PEGylation of amino-modied oligos A1 and A3 was achieved
by reaction with succinimidyl carbonate-activated PEG (Scheme
S1†) followed by purication by high pressure liquid chroma-
tography (HPLC). Successful conjugation was conrmed by
PAGE, HPLC andMALDI-TOFmass spectrometry (Fig. 2A, S2 and
S3† respectively). Subsequent assembly of the conjugates into
supramolecular structures was achieved by a simple mixing/
annealing process. Hybridization of strand PEG-A1 with strand
cholesterol oligo B1 to produce hybrid PEG-A1:B1 led to the
formation of discrete objects, as apparent in dynamic light-
scattering (DLS, Fig. 2C and S4†) and transmission electron
microscopy (TEM). The DLS intensity distribution (Fig. 2C, black
line) is dominated by a population centered at Rh  100 nm with
small populations at 26 and 2 nm. The number distribution
(Fig. 2C, red line), calculated from intensity distribution in the
range 2 < Rh < 10
3 nm, shows a main population with Rh 25 nm
and small population at 60 nm. This agrees well with TEM where
objects approximately 40 nm diameter are observed although
dispersity is higher (Fig. 2D). In addition, labeled hybrids could
be formed by hybridization of PEG-A1 with chol-biotin oligo B2
(hybrid PEG-A1:B2), and PEG-A3 (30-quencher) with chol-uo-
rescein oligo B3 (hybrid PEG-A3:B3, labeled for FRET).
If DNA conjugates are to be used in vitro/vivo then they need
to be stable under physiological conditions. Consequently, the
stability of micellar hybrid PEG-A1:B1 towards degradation by
serum enzymes (including nucleases) was determined by incu-
bation with 10% fetal calf serum (FCS) at 37 C and analysis by
native PAGE. Hybrid PEG-A1:B1 was considerably more stable to
degradation compared to unmodied (i.e. no 30 or 50 modi-
cations) hybrid A2:C (Fig. S6†) with little evident degradation
over 72 h; however, the band-broadening imparted by the
PEGylation makes quantitative analysis diﬃcult. The2372 | Nanoscale, 2014, 6, 2368–2374comparative stability is expected as “spherical nucleic acids”11
have been previously demonstrated to be more stable than the
linear form31 and the additional PEG coating should further
reduce the accessibility of the DNA segments to nucleases.
Strand displacement and unshielding of micelles
The “programmable” responsive unshielding was investigated
by PAGE and FRET analysis. For PAGE experiments, hybrids
were incubated with 1 molar equivalent of either oligonucleo-
tide C (complementary) or D (scrambled) at room temperature.
Samples were then analyzed by native PAGE (Fig. 3A and S7†).
When incubated with complementary oligo C (Lane 7) the band
for hybrid PEG-A1:B1 is lost (cf. Lane 4) and bands for chol oligo
B1 and hybrid PEG-A1:C found in its place (cf. Lanes 3 and
6 respectively). Conversely, when incubated with scrambled
oligo D the PEG-A1:B1 band still remains and no new bands are
observed.‡ Equivalent bands were observed for the hybrids PEG-
A1:B2 and PEG-A3:B3 when analysed in the same manner
(Fig. S7A and B†).
For FRET experiments hybrids PEG-A1:B1 and PEG-A3:B3
were mixed at a 4/1 ratio. PEG-A3:B3 has a uorescein and a
quencher moiety (Black Hole Quencher 1, BHQ-1, Biosearch
Technologies) attached to the 30 ends of the strands forming the
duplex. While the duplex is intact, FRET from the uorescein to
BHQ-1 results in minimal uorescence and an ‘oﬀ’ state. If the
double helix is disrupted FRET is lost resulting in switching ‘on’
of the uorescence (Fig. 3B). Samples were incubated for 10 min
to determine a baseline then 1 equivalent of complementary
oligo C or scrambled oligo D, or an equivalent volume of buﬀer,
was added and emission monitored for a further 30 minutes.
Addition of either oligo D or buﬀer alone results in a minimal
decrease in emission intensity due to a small dilution of the
solution. As expected, addition of oligo C results in a rapid
increase in emission before the uorescence reached a plateau
value. These data agree with that from the PAGE experiments
and conrm that the micelle corona may be removed by addi-
tion of a complementary DNA strand.
Comparison of these data to those for an equivalent
concentration of the chol-uorescein oligo B3 alone conrms
restoration of approximately 45% of the expected uorescence
(Fig. S8B†). Although this is lower than expected it likely results
from incomplete unshielding due to steric hindrance resulting
in some quencher remaining in close enough proximity to the
uorescein to maintain FRET.
Finally, to determine if unpacking could be used for the
presentation of the targeting ligand for binding, micelles of
hybrid PEG-A1:B2 were evaluated in a biotin–avidin binding
assay. Briey, PEG-A1:B2 was mixed with avidin in the presence
of oligo C, oligo D or buﬀer alone. If unpacking is successful the
biotin will bind to the avidin resulting in crosslinking, and
subsequent precipitation, that may be quantied by measuring
the solution turbidity (absorbance at 550 nm, Fig. 3D). TurbidityThis journal is © The Royal Society of Chemistry 2014
Fig. 3 (A) Strand displacement analyzed by PAGE. Lanes: (1) Ladder, (2) PEG-A1, (3) B1, (4) PEG-A1:B1, (5) C, (6) PEG-A1:C, (7) PEG-A1:B1 + C, (8)
D, (9) PEG-A1:B1 + D. (B) Schematic of speciﬁc oligonucleotide detection via disruption of Fo¨rster Resonance Energy Transfer (FRET). When
complementary oligonucleotide is added hybrid PEG-A3:B3 is disrupted resulting in loss of FRET and a consequential increase in ﬂuorescence.
(C) Baseline corrected ﬂuorescence intensity of mixed micelles of PEG-A1:B1 and PEG-A3:B3 (4/1 mole ratio) before and after addition of
complementary oligo C (blue), scrambled oligo D (red), or an equivalent volume of buﬀer (black). (D) Turbidimetry measurements (absorbance at
550 nm) of avidin solutions treated with combinations of PEG-A1:B2, complementary oligo C and scrambled oligo D. Circles represent individual
measurements, lines represent mean and bars represent standard deviation. There is only a detectable increase in absorbance when both PEG-
A1:B2 and oligo C are present.
Fig. 2 (A) Denaturing PAGE of oligonucleotides before and after PEGylation. Lanes: 1. Ladder, 2. A1, 3. PEG-A1, 4. A3, 5. PEG-A3. (B) Native PAGE
of oligonucleotides and hybrids. Lanes: 1. Ladder, 2. PEG-A1, 3. PEG-A3, 4. B1, 5. B2, 6. B3, 7. hybrid PEG-A1:B1, 8. hybrid PEG-A1:B2, 9. hybrid
PEG-A3:B3. (C) Dynamic light-scattering of hybrid PEG-A1:B1. Intensity distribution (black line) and number distribution (red line). (D) Trans-
mission electron micrograph of hybrid PEG-A1:B1 stained with sodium phosphotungstate.
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View Article Onlinemeasurements demonstrate addition of complementary oligo C
results in a signicant increase in absorbance compared to the
avidin treated with PEG-A1:B2 alone (p < 0.0001, 1-way ANOVA);
addition of scrambled oligo D had no eﬀect on absorbance
conrming sequence specic binding. Additionally, to conrm
that turbidity was caused by unpacking and not a sequence
specic interaction between oligo C and avidin, the same
measurement was performed in the absence of PEG-A1:B2 and
no eﬀect on turbidity was observed.
Conclusions
In conclusion we have demonstrated that oligonucleotide
sequences may be used to direct the supramolecular assembly
and unshielding ofmicellar nanoparticles in a pre-programmable
manner. The DNA conjugate micelles formed rapidly and dis-
played high stability to serum enzymes as well as securely
shielding a recognition ligand in the absence of a specic nucleic
acid strand. Unveiling of the ligand by addition of the comple-
mentary strand was easily detected by a simple turbidimetry assayThis journal is © The Royal Society of Chemistry 2014in which the protein, avidin, bound to the exposed biotin signals.
Experiments to evaluate the ability of DNA conjugates to switch in
response to specic sequences in vitro and in vivo are continuing
in our laboratories.32 Programmable control over ligand presen-
tation may have important applications in drug-delivery, e.g.
controlled targeting in the presence of a therapeutic nucleic acid
sequence. In addition, sensing applications can be envisioned for
systems that, like the FRET pair shown herein, canmodulate their
spectral properties in a programmable way allowing for in vitro
and in vivo monitoring of unshielding. Finally, the exibility in
the design and synthesis oﬀered by nucleic acid based materials
combined with the opportunity to tailor polymers and ligands for
specic biomedical tasks suggests materials of this type may
prove useful in the personalized diagnostics and patient-group
stratied therapeutics.
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